vs

Side-by-side financial comparison of Better Home & Finance Holding Co (BETR) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

Better Home & Finance Holding Co is the larger business by last-quarter revenue ($44.3M vs $33.4M, roughly 1.3× Ginkgo Bioworks Holdings, Inc.). On growth, Better Home & Finance Holding Co posted the faster year-over-year revenue change (77.4% vs -23.8%). Ginkgo Bioworks Holdings, Inc. produced more free cash flow last quarter ($-47.7M vs $-167.8M). Over the past eight quarters, Better Home & Finance Holding Co's revenue compounded faster (41.1% CAGR vs -6.2%).

Bajaj Finance Limited (BFL) is an Indian deposit-taking non-banking financial company (NBFC-UL) headquartered in Pune. It has 110.64 million customers and holds assets under management worth ₹462,250 crore (US$55 billion), as of September 2025.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

BETR vs DNA — Head-to-Head

Bigger by revenue
BETR
BETR
1.3× larger
BETR
$44.3M
$33.4M
DNA
Growing faster (revenue YoY)
BETR
BETR
+101.2% gap
BETR
77.4%
-23.8%
DNA
More free cash flow
DNA
DNA
$120.1M more FCF
DNA
$-47.7M
$-167.8M
BETR
Faster 2-yr revenue CAGR
BETR
BETR
Annualised
BETR
41.1%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BETR
BETR
DNA
DNA
Revenue
$44.3M
$33.4M
Net Profit
$-39.9M
Gross Margin
Operating Margin
-3376.8%
-211.9%
Net Margin
-3349.0%
Revenue YoY
77.4%
-23.8%
Net Profit YoY
32.6%
EPS (diluted)
$-2.52
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BETR
BETR
DNA
DNA
Q4 25
$44.3M
$33.4M
Q3 25
$43.9M
$38.8M
Q2 25
$44.1M
$49.6M
Q1 25
$32.6M
$48.3M
Q4 24
$25.0M
$43.8M
Q3 24
$29.0M
$89.0M
Q2 24
$32.3M
$56.2M
Q1 24
$22.3M
$37.9M
Net Profit
BETR
BETR
DNA
DNA
Q4 25
$-39.9M
Q3 25
$-39.1M
$-80.8M
Q2 25
$-36.3M
$-60.3M
Q1 25
$-50.6M
$-91.0M
Q4 24
$-59.2M
Q3 24
$-54.2M
$-56.4M
Q2 24
$-41.4M
$-217.2M
Q1 24
$-51.5M
$-165.9M
Operating Margin
BETR
BETR
DNA
DNA
Q4 25
-3376.8%
-211.9%
Q3 25
-88.9%
-231.8%
Q2 25
-81.9%
-132.1%
Q1 25
-154.9%
-184.1%
Q4 24
-1428.3%
-236.3%
Q3 24
-186.5%
-62.0%
Q2 24
-127.6%
-396.7%
Q1 24
-230.8%
-469.1%
Net Margin
BETR
BETR
DNA
DNA
Q4 25
-3349.0%
Q3 25
-89.2%
-207.9%
Q2 25
-82.2%
-121.6%
Q1 25
-155.3%
-188.2%
Q4 24
-1437.5%
Q3 24
-187.0%
-63.3%
Q2 24
-128.2%
-386.4%
Q1 24
-231.4%
-437.3%
EPS (diluted)
BETR
BETR
DNA
DNA
Q4 25
$-2.52
$-1.41
Q3 25
$-2.56
$-1.45
Q2 25
$-2.39
$-1.10
Q1 25
$-3.33
$-1.68
Q4 24
$-3.92
$-1.91
Q3 24
$-3.58
$-1.08
Q2 24
$-2.74
$-4.23
Q1 24
$-3.41
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BETR
BETR
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$203.4M
$422.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$37.2M
$508.6M
Total Assets
$1.5B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BETR
BETR
DNA
DNA
Q4 25
$203.4M
$422.6M
Q3 25
$205.8M
$495.5M
Q2 25
$221.5M
$559.4M
Q1 25
$228.0M
$325.3M
Q4 24
$264.9M
$561.6M
Q3 24
$262.1M
$616.2M
Q2 24
$378.8M
$730.4M
Q1 24
$482.6M
$840.4M
Stockholders' Equity
BETR
BETR
DNA
DNA
Q4 25
$37.2M
$508.6M
Q3 25
$41.9M
$559.8M
Q2 25
$76.6M
$613.0M
Q1 25
$-102.1M
$647.4M
Q4 24
$-58.2M
$716.1M
Q3 24
$388.0K
$797.9M
Q2 24
$44.9M
$833.1M
Q1 24
$76.3M
$987.3M
Total Assets
BETR
BETR
DNA
DNA
Q4 25
$1.5B
$1.1B
Q3 25
$1.4B
$1.2B
Q2 25
$1.2B
$1.2B
Q1 25
$1.0B
$1.3B
Q4 24
$913.1M
$1.4B
Q3 24
$845.2M
$1.5B
Q2 24
$957.9M
$1.6B
Q1 24
$841.6M
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BETR
BETR
DNA
DNA
Operating Cash FlowLast quarter
$-166.6M
$-47.7M
Free Cash FlowOCF − Capex
$-167.8M
$-47.7M
FCF MarginFCF / Revenue
-378.6%
-142.8%
Capex IntensityCapex / Revenue
2.7%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-277.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BETR
BETR
DNA
DNA
Q4 25
$-166.6M
$-47.7M
Q3 25
$4.2M
$-31.6M
Q2 25
$-56.3M
$-40.3M
Q1 25
$-57.2M
$-51.5M
Q4 24
$-380.0M
$-42.4M
Q3 24
$-10.6M
$-103.5M
Q2 24
$-220.6M
$-84.4M
Q1 24
$-42.8M
$-89.3M
Free Cash Flow
BETR
BETR
DNA
DNA
Q4 25
$-167.8M
$-47.7M
Q3 25
$4.0M
Q2 25
$-56.7M
$-40.3M
Q1 25
$-57.4M
$-59.1M
Q4 24
$-383.4M
$-56.1M
Q3 24
$-11.7M
$-118.6M
Q2 24
$-221.8M
$-111.4M
Q1 24
$-43.3M
$-96.0M
FCF Margin
BETR
BETR
DNA
DNA
Q4 25
-378.6%
-142.8%
Q3 25
9.1%
Q2 25
-128.5%
-81.2%
Q1 25
-176.3%
-122.4%
Q4 24
-1534.6%
-128.0%
Q3 24
-40.5%
-133.2%
Q2 24
-687.6%
-198.2%
Q1 24
-194.5%
-252.9%
Capex Intensity
BETR
BETR
DNA
DNA
Q4 25
2.7%
0.0%
Q3 25
0.5%
0.0%
Q2 25
0.9%
0.1%
Q1 25
0.6%
15.8%
Q4 24
13.6%
31.3%
Q3 24
4.1%
16.9%
Q2 24
3.9%
48.1%
Q1 24
2.1%
17.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BETR
BETR

Segment breakdown not available.

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons